Literature DB >> 12495474

Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR.

Hisataka Fujiwara1, Masanori Terashima, Takashi Irinoda, Akinori Takagane, Kaoru Abe, Masahiro Kashiwaba, Kennichi Oyama, Masanori Takahashi, Chihaya Maesawa, Kazuyoshi Saito, Teiji Takechi, Masakazu Fukushima.   

Abstract

We used real-time reverse-transcription polymerase chain reaction (RT-PCR) to assay expression of the mRNA of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in gastric cancer tissue with the objective of establishing a system to measure TS and DPD in ultra-low-volume samples. Nude mouse xenografts of 5 human gastric cancer cell lines and 85 clinical samples were used as the specimens in this study. Sensitivity to 5-fluorouracil (5-FU) was determined on the basis of the relative tumor proliferation rate in mice and the results of ATP assay using serum-free cultures of the clinical samples. mRNA expression was measured in tumor tissue by real-time RT-PCR using the ABI PRISM 7700 system. The values for expression of the mRNA for TS and DPD were corrected according to the level of glyceraldehyde-3-phosphate dehydrogenase mRNA expression. The xenografts yielded correlations between TS and DPD mRNA expression and the activity of the enzymes (TS: rs=0.700, DPD: rs=0.900), and an inverse correlation was noted between the mRNA levels and sensitivity to 5-FU (TS: rs=-0.900, DPD: rs=-0.800). The clinical samples showed an inverse correlation between 5-FU sensitivity and mRNA expression (TS: rs=-0.518, DPD: rs=-0.564). Sensitivity to 5-FU was noted only in cases in which TS mRNA expression and DPD mRNA expression were both low. Real-time RT-PCR can provide a highly sensitive assessment of TS and DPD mRNA expression in gastric cancer, and it was useful for predicting 5-FU sensitivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495474      PMCID: PMC5926932          DOI: 10.1111/j.1349-7006.2002.tb01243.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  33 in total

Review 1.  Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase.

Authors:  G J Peters; C L van der Wilt; C J van Groeningen
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

2.  Effect of 5-fluorouracil on the synthesis and translation of polyadenylic acid-containing RNA from regenerating rat liver.

Authors:  C K Carrico; R I Glazer
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

3.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Authors:  Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

Review 4.  Chemotherapy of gastric cancer.

Authors:  D L Schipper; D J Wagener
Journal:  Anticancer Drugs       Date:  1996-02       Impact factor: 2.248

Review 5.  Clinical implications of dihydropyrimidine dehydrogenase inhibition.

Authors:  R B Diasio
Journal:  Oncology (Williston Park)       Date:  1999-07       Impact factor: 2.990

6.  Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer.

Authors:  Y Ishikawa; T Kubota; Y Otani; M Watanabe; T Teramoto; K Kumai; T Takechi; H Okabe; M Fukushima; M Kitajima
Journal:  Anticancer Res       Date:  1999 Nov-Dec       Impact factor: 2.480

Review 7.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

8.  Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor.

Authors:  J L Fischel; P Formento; M C Etienne; T Spector; N Renée; G Milano
Journal:  Biochem Pharmacol       Date:  1997-06-01       Impact factor: 5.858

9.  FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.

Authors:  D Kelsen; O T Atiq; L Saltz; D Niedzwiecki; D Ginn; D Chapman; R Heelan; C Lightdale; V Vinciguerra; M Brennan
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.

Authors:  A Beck; M C Etienne; S Chéradame; J L Fischel; P Formento; N Renée; G Milano
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

View more
  9 in total

1.  Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.

Authors:  Wenqi Bai; Yueqin Wu; Ping Zhang; Yanfeng Xi
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.

Authors:  Rentian Wu; Qian Nie; Erin E Tapper; Calvin R Jerde; Garrett S Dunlap; Shikshya Shrestha; Tarig A Elraiyah; Steven M Offer; Robert B Diasio
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

3.  Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

Authors:  Masanori Terashima; Hisataka Fujiwara; Akinori Takagane; Kaoru Abe; Takashi Irinoda; Tsutomu Nakaya; Hitoshi Yonezawa; Kenichi Oyama; Kazuyoshi Saito; Norio Kanzaki; Satoshi Ohtani; Tsuyoshi Nemoto; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

4.  Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.

Authors:  Eiji Sasaki; Kazunari Tominaga; Hikaru Kuwamura; Toshio Watanabe; Yasuhiro Fujiwara; Nobuhide Oshitani; Kazuhide Higuchi; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

5.  Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.

Authors:  Ji-Yeon Kim; Eun Shin; Jin Won Kim; Hye Seung Lee; Dae-Won Lee; Se-Hyun Kim; Jeong-Ok Lee; Yu Jung Kim; Jee Hyun Kim; Soo-Mee Bang; Sang-Hoon Ahn; Do Joong Park; Jong Seok Lee; Ju-Seog Lee; Hyung-Ho Kim; Keun-Wook Lee
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 6.  The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis.

Authors:  Cong Zhang; Hongpeng Liu; Bin Ma; Yongxi Song; Peng Gao; Yingying Xu; Dehao Yu; Zhenning Wang
Journal:  Dis Markers       Date:  2017-01-31       Impact factor: 3.434

7.  P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.

Authors:  Prashanth Gokare; Niklas K Finnberg; Phillip H Abbosh; Jenny Dai; Maureen E Murphy; Wafik S El-Deiry
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

8.  Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.

Authors:  Kenzo Iizuka; Cheng Jin; Kokoro Eshima; Mei Hua Hong; Kiyoshi Eshima; Masakazu Fukushima
Journal:  Drug Des Devel Ther       Date:  2018-03-29       Impact factor: 4.162

9.  Choice of Capecitabine or S1 in Combination with Oxaliplatin based on Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase Expression Status in Patients with Advanced Gastric Cancer.

Authors:  Rong Xu; Xiaolei He; Reyina Wufuli; Ying Su; Lili Ma; Ru Chen; Zhongcheng Han; Fang Wang; Jiang Liu
Journal:  J Gastric Cancer       Date:  2019-11-13       Impact factor: 3.720

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.